Schedule of Contract Assets and Contract Liabilities

Total contract assets at June 30, 2023 were as follows:


(In thousands)	Contract Assets
Contract assets at December 31, 2022	$	8,929
Additions		10,115
Transferred to receivables, net		(19,044	)
Contract assets at June 30, 2023	$	—

Total contract liabilities at June 30, 2023 were as follows:


(In thousands)	Contract Liabilities
Contract liabilities at December 31, 2022	$	10,701
Additions		(932	)
Amounts recognized into revenue		(4,101	)
Contract liabilities at June 30, 2023	$	5,668

Schedule of Disaggregation of Revenues

During the three and six months ended June 30, 2023 and 2022, the Company recorded product sales, net, as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2023		2022		2023		2022
VIVITROL	$	102,071	$	96,105	$	198,730	$	180,959
ARISTADA and ARISTADA INITIO		82,409		74,622		162,486		147,107
LYBALVI		46,997		20,060		84,988		33,989
Total product sales, net	$	231,477	$	190,787	$	446,204	$	362,055

Schedule of Disaggregation of Revenues

During the three and six months ended June 30, 2023 and 2022, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:


	Three Months Ended June 30, 2023						Six Months Ended June 30, 2023
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total		Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	321,239	$	321,239	$	—	$	334,801	$	334,801
VUMERITY		10,369		21,926		32,295		23,018		38,151		61,169
RISPERDAL CONSTA		4,901		240		5,141		15,317		806		16,123
Other		16,628		10,610		27,238		32,003		14,679		46,682
	$	31,898	$	354,015	$	385,913	$	70,338	$	388,437	$	458,775


	Three Months Ended June 30, 2022						Six Months Ended June 30, 2022
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total		Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	26,648	$	26,648	$	—	$	63,702	$	63,702
VUMERITY		5,650		20,520		26,170		17,045		39,720		56,765
RISPERDAL CONSTA		8,571		1,820		10,391		24,149		3,668		27,817
Other		11,353		10,764		22,117		23,207		19,005		42,212
	$	25,574	$	59,752	$	85,326	$	64,401	$	126,095	$	190,496

(1)

“Long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate)